In response to: Benefit of neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction.

Similar Items

• Clinical Correlates and Outcomes of Dual Basiliximab and Antithymocyte Globulin Induction in Kidney Transplant Recipients: A National Study
  by: Ngan N. Lam, MD, et al.
  Published: (2021-08-01)
• Acute Respiratory Distress Syndrome in Young Postrenal Transplant Patients Receiving Basiliximab
  by: Kalkena Sivanesam, et al.
  Published: (2025-01-01)
• Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience
  by: Masashi Furukawa, et al.
  Published: (2022-06-01)
• Basiliximab is superior to low dose rabbit anti-thymocyte globulin in pediatric kidney transplant recipients: The younger, the better
  by: Lan Zhu, et al.
  Published: (2025-01-01)
• Outcomes of thymoglobulin versus basiliximab induction therapies in living donor kidney transplant recipients with mild to moderate immunological risk – a retrospective analysis of UNOS database
  by: Hatem Ali, et al.
  Published: (2023-12-01)